albumin bound paclitaxel II (SYHX2011) / CSPC Pharma - LARVOL DELTA

Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial. (PubMed, Biomol Biomed) - "Descriptive trends toward longer PFS and OS with SYHX2011 were observed across hormone receptor-positive, triple-negative, first-line, and later-line subgroups. Although OS data remain immature and subgroup findings require cautious interpretation, the updated results support continued clinical evaluation of SYHX2011 as an albumin-bound paclitaxel option for advanced breast cancer."

Clinical • Journal • P3 data • Breast Cancer • Dermatology • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study. (PubMed, Cancer Commun (Lond)) - P3 | "Trial registration: ClinicalTrials.gov identifier: NCT05753865. Date of registration: 2023 February 22."

Clinical • Journal • P3 data • Breast Cancer • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Pain • Solid Tumor

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=396 | Not yet recruiting | Sponsor: Shanghai Chest Hospital

New P2/3 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1 • ROS1

Efficacy and safety of Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-blind Phase III study (SABCS 2025) - P3 | "SYHX2011 demonstrated superior efficacy and significantly reduced the incidence of rash compared with PAB. SYHX2011 might be a more effective and safe treatment option for patients with advanced breast cancer."

Clinical • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor

A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Metastases • New P2 trial • Breast Cancer • Oncology • Solid Tumor

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) (clinicaltrials.gov) - P3 | N=454 | Not yet recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Metastases • New P3 trial • Breast Cancer • Oncology • Solid Tumor